Advertisement
Research Article| Volume 29, ISSUE 7, P629-634, April 01, 1991

High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients

  • Hubert J. Coppens
    Footnotes
    Affiliations
    From the Department of Clinical Psychiatry, of the Groningen University, and the Psychiatric Hospital “Licht en Kracht”, Assen (Slooff, the Netherlands
    Search for articles by this author
  • Cees J. Slooff
    Footnotes
    Affiliations
    From the Department of Clinical Psychiatry, of the Groningen University, and the Psychiatric Hospital “Licht en Kracht”, Assen (Slooff, the Netherlands
    Search for articles by this author
  • Anne M.J. Paans
    Footnotes
    Affiliations
    Department of Nuclear Medicine, of the Groningen University, and the Psychiatric Hospital “Licht en Kracht”, Assen (Slooff, the Netherlands
    Search for articles by this author
  • Tonnie Wiegman
    Footnotes
    Affiliations
    Department of Nuclear Medicine, of the Groningen University, and the Psychiatric Hospital “Licht en Kracht”, Assen (Slooff, the Netherlands
    Search for articles by this author
  • Willem Vaalburg
    Footnotes
    Affiliations
    Department of Nuclear Medicine, of the Groningen University, and the Psychiatric Hospital “Licht en Kracht”, Assen (Slooff, the Netherlands
    Search for articles by this author
  • Jakob Korf
    Correspondence
    Address reprint requests to J. Korf, Department of Biological Psychiatry, Psychiatric University Clinic, Oostersingel 59, NL 9713 EZ Groningen, the Netherlands.
    Footnotes
    Affiliations
    Department of Biological Psychiatry, of the Groningen University, and the Psychiatric Hospital “Licht en Kracht”, Assen (Slooff, the Netherlands
    Search for articles by this author
  • Author Footnotes
    ∗ The help of Drs. J.W. Louwerens and D. Tulner is greatly appreaciated.
DOI:https://doi.org/10.1016/0006-3223(91)90132-6
High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients
Previous ArticleReal eyes realize real lies
Next ArticleThe latent inhibition model of schizophrenic attention disorder Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      We investigated whether the lack of therapeutic response to long-term and adequate neuroleptic treatment was due to a failure to achieve a blockade of cerebral dopamine receptors. Six chronic schizophrenic and medicated patients (DSM-III-R diagnosis, paranoid or disorganized type) were assessed with the Present State Examination and the Brief Psychiatric Rating Scale. According to the Chouinard Rating Scale there were little extrapyramidal symptoms, although no anticholinergic drugs were given. Plasma levels of the neuroleptics were determined and found in the therapeutic range or higher. Dopamine D2-receptor occupancy was determined with positron emission tomography using 11C-methylspiperone as ligand. There was a more than 95% blockade of the D2 receptors in the striatum. These results indicate that the lack of therapeutic response and extrapyramidal side effects cannot be attributed to an incomplete blockade of cerebral D2 receptors and that the pathogenetic role of these receptors can be questioned in therapy-resistant schizophrenic patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Baldessarini R.J.
        • Cohen B.M.
        • Teicher M.H.
        Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis.
        Arch Gen Psychiatry. 1988; 45: 79-91
        • Burns H.D.
        • Dannals R.F.
        • Langstrom B.
        • et al.
        Math Eq, a ligand binding to dopmaine receptors: Radiochemical synthesis and biodistribution in mice.
        J Nucl Med. 1984; 25: 1222-1227
        • Cooper J.K.
        • Mckay G.
        • Miohla K.K.
        Submicrogram quantification of chlorpromazine in plasma by high-performance liquid chromatography with electrochemical detection.
        J Pharmacol Sci. 1983; 72: 1259-1262
        • Coppens H.J.
        • Slooff C.J.
        • Paans A.M.J.
        • Vaalburg W.
        • Louwerens J.W.
        • Korf J.
        PET-scanning with C11-labeled methylspiperon and prolactin provocation tests in therapy-resistant psychotic patients (Abstract).
        Psychopharmacology. 1988; 83 (34.03.12)
        • Crow T.J.
        Molecular pathology of schizophrenia: More than one disease process?.
        Br med J. 1980; 280: 66-68
        • Crow T.J.
        The two syndrome concept: Origins and current status.
        Schizophr Bull. 1985; 11: 471
        • Dahl S.G.
        Plasma level monitoring of antipsychotic drugs: Clinical utility.
        Clin Pharmacokinet. 1986; 11: 36-61
        • Davis J.M.
        • Andriukaitis J.
        The natural course of schizophrenia and effective maintenance drug treatment.
        J Clin Psychopharmacol. 1986; 6: 25-105
        • Dhar A.K.
        • Kutt H.
        Improved liquid chromatography determination of haloperidol in plasma.
        Clin Chem. 1984; 30: 1228-1230
        • Farde L.
        • Wiesel F.-A.
        • Halldin C.
        • Sedvall G.
        Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.
        Arch Gen Psychiatry. 1988; 45: 71-76
        • Farde L.
        • Wiesel F.A.
        • Jansson P.
        • Uppfeldt G.
        • Wahlen G.
        • Sedvall G.
        An open label trial of raclopride in acute schizophrenia: Conformation of D2-dopamine receptor occupancy by PET.
        Psychopharmacology. 1988; 94: 1-7
        • Götze P.
        • Kühne D.
        Zur Problematik Schizophrener: Schizophrenicähnlicher Psychosen nach Schördel-Hirn-Trannen.
        Nervenarzt. 1987; 49: 361-365
        • Keefe R.S.E.
        • Moha R.C.
        • Losonczy M.F.
        • et al.
        Characteristics of very poor outcome schizophrenia.
        Am J Psychiatry. 1987; 144: 889-895
        • Mazière B.
        • Loch C.
        • Baron J.C.
        • et al.
        In vivo quantitative imaging of dopamine receptors in human brain using positron tomograph and [76Br]-bromospiperone.
        Eur J Pharmacol. 1985; 114: 267-272
        • Paans A.M.J.
        • Vaalburg W.
        • Woldring M.G.
        A rotating double-headed positron camera.
        J Nucl Med. 1985; 26: 1466-1471
        • Rutgers A.W.F.
        • Lakke J.P.W.F.
        • Paans A.M.J.
        • Vaalburg W.
        • Korf J.
        Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography.
        J Neurol Sci. 1987; 80: 237-247
        • Seeman P.
        • Ulpian C.
        • Bergeron C.
        • et al.
        Bimodal distribution of dopamine receptor densities in brains of schizophrenics.
        Science. 1984; 225: 728-731
        • Wing J.K.
        • Cooper J.E.
        • Sartorius N.
        The Measurement and Classification of Psychiatric Symptomatology.
        Cambridge University Press, 1974
        • Wolkin A.
        • Barouche F.
        • Wolf A.F.
        • et al.
        Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia.
        Am J Psychiatry. 1989; 46: 905-908
        • Wong D.F.
        • Wagner H.N.
        • Larry E.T.
        • et al.
        Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.
        Science. 1986; 234: 1558-1563

      Article info

      Publication history

      Received in revised form: October 3, 1990
      Received: July 2, 1989

      Footnotes

      ☆This study was supported in part by Squibb BV (the Netherlands).

      Identification

      DOI: https://doi.org/10.1016/0006-3223(91)90132-6

      Copyright

      © 1991 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX